Candriam SCA’s Achilles Therapeutics ACHL Stock Holding History

Candriam SCA’s Portfolio ACHL Stock Details ACHL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-161,624	Closed	-$1.58M	–	921
2021 Q2	$1.58M	Buy	+161,624	New	+$2.19M	0.01%	628

Other funds holding ACHL

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Point72 Asset Management

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Candriam SCA's ACHL Position: Q3 2021 in Review

Candriam SCA sold out of Achilles Therapeutics (ACHL) in Q3 2021, closing a stake of 161,624 shares — an estimated $1.58M sold.

Candriam SCA first reported a position in ACHL in Q2 2021 and held it in 1 quarter. The position peaked at $1.58M in Q2 2021. 20 funds tracked by Wall St. Rank hold ACHL as of Q3 2021.

Candriam SCA reported no remaining Achilles Therapeutics position as of Q3 2021 after selling out during the quarter.
Candriam SCA sold 161,624 Achilles Therapeutics shares in Q3 2021, an estimated $1.58M.
Candriam SCA first reported a position in Achilles Therapeutics in Q2 2021 and held it in 1 quarter.
Candriam SCA's Achilles Therapeutics position peaked at $1.58M in Q2 2021.
20 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q3 2021.

Based on Candriam SCA's 13F filing for Q3 2021, filed 9 Nov 2021.